Drug Profile
Ervogastat - Pfizer
Alternative Names: DGAT2i; PF-06865571Latest Information Update: 31 May 2022
Price :
$50
*
At a glance
- Originator Pfizer
- Class Hepatoprotectants; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Diacylglycerol O acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 26 May 2022 Ervogastat - Pfizer receives Fast Track designation for Non-alcoholic steatohepatitis [PO,Tablet] (Combination therapy) in USA
- 26 May 2022 Pfizer plans a phase III programme for Non-alcoholic steatohepatitis
- 08 Dec 2021 Pfizer completes phase I drug-drug interaction trial in healthy volunteers in USA (NCT04839393)